Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia

Bibliography

• Stahl S. Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge: CUP; 2002
   Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
   PubMed Web of Science ®Google Scholar
• Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs 2006;20:233-55
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Exp Opin Drug Saf 2006;7:1825-34
   Web of Science ®Google Scholar
• Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S3-9
   PubMed Web of Science ®Google Scholar
• Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-42
   Web of Science ®Google Scholar
• Hyttel L, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha one receptors. J Neural Trasm 1992;89:61-9
   PubMed Web of Science ®Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikowa-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409
   PubMed Web of Science ®Google Scholar
• Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000;295:226-32
   PubMed Web of Science ®Google Scholar
• Hietala J, Kuoppamaki M, Majasuo H, et al. Sertindole is a serotonin 5-HT2C inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment. Psychopharmacology 2001;157:180-7
   PubMed Web of Science ®Google Scholar
• Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extrastriatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002;162:37-41
   PubMed Web of Science ®Google Scholar
• Petit-Taboué MC, Landeau B, Barré L, et al. Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human cortex. J Nucl Med 1999;40:25-32
   PubMed Web of Science ®Google Scholar
• Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match position paradigm. Eur J Pharmacol 1995;281:241-50
   PubMed Web of Science ®Google Scholar
• Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris Water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 1996;124:126-33
   PubMed Web of Science ®Google Scholar
• Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006;542:108-15
   PubMed Web of Science ®Google Scholar
• Didriksen M, Skarfeldt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris'water maze by sertindole and other antipsychotics. Psychopharmacology 2007;193:225-33
   PubMed Web of Science ®Google Scholar
• Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6; receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2007 [Epub ahead of print]
   PubMedGoogle Scholar
• Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsde de pointes and sudden death. Drug Saf 2005;28:35-51
   PubMed Web of Science ®Google Scholar
• Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788-93
   PubMed Web of Science ®Google Scholar
• Kongsamut S, Kang J, Chen XL, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71
   PubMed Web of Science ®Google Scholar
• Drici MD, Wang WX, Liu XK, et al. Prolongation of QT interval in isolated feline hearths by antipsychotic drugs. J Clin Psychopharmacol 1998;18:477-81
   PubMed Web of Science ®Google Scholar
• Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterisation of the antipsychotic drug sertindole in a rabbit hearth model of Torsade de Pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002;300:64-71
   PubMed Web of Science ®Google Scholar
• Thomsen MB, Volders PGA, Stengl M, et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 2003;307:776-84
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Eckardt L, Matz J. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S11-20
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatment: focus on sertindole. Int J Neuropsychopharmacol 2005;8:615-29
   PubMed Web of Science ®Google Scholar
• Wong SL, Linen P, Mack RJ, Granneman GR. Effects of food, antacid, and dosage form on the phamacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos 1997;18:533-41
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack RJ, Granneman GR. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997;62:157-64
   PubMed Web of Science ®Google Scholar
• Wong SL, Menacherry S, Mulford D, et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7
   PubMed Web of Science ®Google Scholar
• Wong SL, Granneman R. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. J Pharm Sci 1998;87:1629-31
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. Serdolect (sertindole) monograph. Copenhagen: H Lundbeck A/S; 2005
   Google Scholar
• Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005;33:165-74
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 2006;187:415-23
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
   PubMed Web of Science ®Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychtics. J Clin Psychiatry 1996;57(Suppl 11):12-25
   PubMed Web of Science ®Google Scholar
• Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 1998;135:236-41
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack R, Granneman GR. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:146-51
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997;37:1056-61
   PubMed Web of Science ®Google Scholar
• Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91
   PubMed Web of Science ®Google Scholar
• Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a Phase III trial. Int J Psychiatry Clin Pract 2000;4:55-62
   PubMed Web of Science ®Google Scholar
• Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9
   PubMed Web of Science ®Google Scholar
• Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49-56
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Mack RJ, Granneman GR, et al. Sertindole in the treatment of psychosis in the schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997;12(Suppl 1):S29-35
   PubMedGoogle Scholar
• Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
   PubMed Web of Science ®Google Scholar
• Gallhofer B, Jaanson P, Mittoux A, et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-86
   PubMed Web of Science ®Google Scholar
• Hale A, Azorin JM, Kasper S, et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a Phase III trial. Int J Psychiatry Clin Pract 2000;4:47-54
   PubMed Web of Science ®Google Scholar
• Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005;3:CD001715
   Google Scholar
• Perquin LN. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 2005;20:335-8
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
   PubMed Web of Science ®Google Scholar
• Kasper S, Tuomi M. The clinical safety and tolerability profile of sertindole [abstract no. S422]. Int J Neuropsychopharmacol 2004;7(Suppl 1):S422
   Web of Science ®Google Scholar
• Mack R, Driscoll R, Silber C. The long term cardiovascular safety of sertindole. Eur Neuropsychopharmacol 1997;7(Suppl 2):S207
   Google Scholar
• Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and in the presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
   PubMed Web of Science ®Google Scholar
• Wilton L, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6
   PubMed Web of Science ®Google Scholar
• Branford D, Thompson B, Mouldon C. Mortality in three comparative cohorts of patients who received sertindole, risperidone and olanzapine: a hospital-based, retrospective study [abstract no. 247]. Pharmacoepidemiol Drug Saf 2002;11(Suppl 1):S116
   Google Scholar
• Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007;16:804-11
   PubMed Web of Science ®Google Scholar
• Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003;12:271-81
   PubMed Web of Science ®Google Scholar